pdufa.bio

UX111

Page updated ·next FDA decision on the calendar ·Data as of Oct 13, 2026 11:39 PM ET

UX111 The FDA issued a Complete Response Letter on Jul 11, 2025. 1 FDA decision on record below. Every date links its source.

RARE catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Jul 11, 2025 CRLRARE

Specialist biotech funds holding RARE, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
RTW Investments7,796,895$260.3 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is UX111's next FDA decision or readout?

No upcoming catalyst is on our calendar for UX111; 1 FDA decision is on record below.

What happened at UX111's most recent FDA decision?

On Jul 11, 2025 the FDA issued a Complete Response Letter. The decision page carries the source document and the measured share-price reaction.

Has UX111 been approved by the FDA?

Not in our records. The FDA issued a Complete Response Letter on Jul 11, 2025.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.